Progesterone Therapy and Preterm Birth Prevention

The Women and Infant Health Program at the Wyoming Department of Health is focusing on prevention of preterm birth as part of our efforts to reduce infant mortality. We are conducting a survey of Wyoming providers to learn about the use of progesterone therapy, 17 alpha-hydroxyprogesterone caproate (17P), to prevent recurrent preterm delivery (in women with a prior spontaneous singleton preterm birth) and to better understand any existing barriers to its use in Wyoming.

Thank you for your time and effort in completing the survey. Please add any additional comments that would further inform us about your experience using progesterone therapy. If you have any questions, please contact Ashley Busacker at ashley.busacker@wyo.gov 307-777-6936, or Danielle Marks Danielle.marks@wyo.gov 307-777-7944.

Question Title

* 1. What is the name of the your clinic or practice?

Question Title

* 2. Type of practice

OB/GYN Practice

General/Family Practice

Other (please specify)

Question Title

* 3. Number of providers in your practice:

MD/DO

Nurse Practitioner

Physician Assistant

Certified Nurse Midwife

Question Title

* 4. Do you have a protocol for identifying potential candidates for progesterone therapy?

Yes

Question Title

* 5. Is history of previous spontaneous singleton preterm delivery asked when women call to schedule their first prenatal care appointment?

Yes

No, history is obtained at first prenatal appointment

Question Title

* 6. Do you prescribe intramuscular 17 alpha-hydroxyprogesterone caproate (17P) therapy for prevention of recurrent preterm delivery among women who have had a history of spontaneous preterm delivery in a prior singleton pregnancy?

Yes